Down-modulation of host reactivity by anti-CD44 in skin transplantation

Transplantation

Volumn 66, Issue 6, 1998, Pages 778-791

  Seiter, Simone ^a,b   Weber, Bernd ^a   Tilgen, Wolfgang ^b   Zöller, Margot ^a,c  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c UNIVERSITY OF KARLSRUHE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; HERMES ANTIGEN;

ANIMAL EXPERIMENT; ARTICLE; CYTOTOXIC T LYMPHOCYTE; DESENSITIZATION; DOSE RESPONSE; DOWN REGULATION; FULL THICKNESS SKIN GRAFT; HELPER CELL; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PRIORITY JOURNAL; RAT; SKIN TRANSPLANTATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD44; CYCLOSPORINE; FEMALE; GRAFT REJECTION; IMMUNOSUPPRESSIVE AGENTS; MALE; PROTEIN ISOFORMS; RATS; RATS, INBRED STRAINS; SKIN TRANSPLANTATION;

EID: 0032572989     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199809270-00013     Document Type: Article

References (98)

1. Rosenberg AS, Singer A. Cellular basis of skin allograft rejection: an in vivo model of immune mediated tissue destruction. Annu Rev Immunol 1992; 10: 333.
2. Keenan RJ, Zeevi A. Immunological consequences of transplantation. Chest Surg Clin North Am 1995; 5: 107.
3. Cuturi MC, Blancho G, Josien R, Soulillou P. The biology of allograft rejection. Curr Opin Nephrol Hypertens 1994; 3: 578.
4. Gammie JS, Colson YL, Griffith BP, Pham SM. Chimerism and thoracic organ transplantation. Semin Thorac Cardiovasc Surg 1996; 8: 149.
5. Gardner CR. The pharmacology of immunosuppressant drugs in skin transplant rejection in mice and other rodents. Gen Pharmacol 1995; 26: 245.
6. Morris RE. New small molecule immunosuppressants for transplantation: review of essential concepts. J Heart Lung Transplant 1993; 12: 275.
7. Masri MA. Comparative study of toxicity and efficacy of cyclosporine, cyclosporine G (OG37), FK 506, and rapamycin in BALB/c mice with fitted skin grafts. Transplant Proc 1995; 27: 366.
8. Kivisto KT. A review of assay methods for cyclosporin: clinical implications. Clin Pharmacokinet 1992; 23: 173.
9. Hooks MA. Tacrolimus, a new immunosuppressant: a review of the literature. Ann Pharmacother 1994; 28: 501.
10. Masri MA. Comparative study of skin graft survival rates in BALB/c mice treated with either cyclosporine A, cyclosporine G or 1/1 combination of both. Transplant Proc 1992; 24: 1661.
11. Graham RM. Cyclosporine: mechanisms of action and toxicity. Cleve Clin J Med 1994; 61: 308.
12. Gianello PR, Blancho G, Fishbein JF, et al. Mechanism of cyclosporin-induced tolerance to primarily vascularized allografts in miniature swine: effect of administration of exogenous IL-2. J Immunol 1994; 153: 4788.
13. Dupuy P, Bagot M, Michl L, Descourt B, Dubertret L. Cyclosporin A inhibits the antigen-presenting functions of freshly isolated human Langerhans cells in vitro. J Invest Dermatol 1991; 96: 408.
14. Magae J, Matsubara H, Aotsuka N, Kurasawa K, Shearer GM. Interleukin-2 does not overcome suppression of graft rejection by cyclosporin: effect of cyclosporin A on T cell properties in vivo. Cell Immunol 1996; 173: 276.
15. Gaston RS. Cytokines and transplantation: a clinical perspective. Transplant Sci 1994; 4 (suppl 1): 9.
16. Chandler C, Passaro E Jr. Transplant rejection: mechanisms and treatment. Arch Surg 1993; 128: 279.
17. Yuan ZF, Bailey RR, Gardner J. Cyclosporin in renal transplantation: a 9 year experience. N Z Med J 1995; 108: 29.
18. Textor SC, Canzanello VJ, Taler SJ, et al. Cyclosporin-induced hypertension after transplantation. Mayo Clin Proc 1994; 69: 1182.
19. Deschler DG, Osorio R, Ascher NL, Lee KC. Posttransplantation lymphoproliferative disorder in patients under primary tacrolimus (FK 506). Arch Otolaryngol Head Neck Surg 1995; 121: 1037.
20. Soroseno W. A review of the mechanisms of oral tolerance and immunotherapy. J R Soc Med 1995; 88: 14.
21. Davies JD, Martin G, Phillips J, Marshall SE, Cobbold SP, Waldmann H. T cell regulation in adult transplantation tolerance. J Immunol 1996; 157: 529.
22. De-Fazio SR, Plowey JM, Hartner WC, Gozzo JJ. Late adjunctive therapy with single doses of rapamycin in skin-allografted mice treated with antilymphocyte serum and donor bone marrow cells. Transpl Immunol 1996; 4: 105.
23. Gorczynski RM, Wojcik D. A role for nonspecific (cyclosporin A) or specific (monoclonal antibodies to ICAM-1, LFA-1, and IL-10) immunomodulation in the prolongation of skin allografts after antigen-specific pretransplant immunization or transfusion. J Immunol 1994; 152: 2011.
24. Gorczynski RM, Fu XM, Chung S, Sullivan B, Chen Z. Manipulation of xenogeneic skin and/or renal graft survival in the rat-mouse concordant combination by portal vein pretransplant transfusion. Transpl Immunol 1995; 3: 321.
25. Brennan DC, Mohanakumar T, Flye MW. Donor-specific transfusion and donor bone marrow infusion in renal transplantation tolerance: a review of efficacy and mechanisms. Am J Kidney Dis 1995; 26: 701.
26. Roelen DL, Dover EL, Niimi M, Young NT, Morris PJ, Wood KJ. Semi-aoologeneic (F1) versus fully allogeneic blood transfusions: differences in their ability to induce specific immunological unresponsiveness. Eur J Immunol 1996; 26: 1468.
27. Chatenoud L, Bach JF. Selective immunosuppression with anti-T cell monoclonal antibodies. Clin Nephrol 1992; 38 (suppl 1): 53.
28. Parlevliet KL, Schellekens PT. Monoclonal antibodies in renal transplantation: a review. Transpl Int 1992; 5: 234.
29. Cobbold SP, Adams E, Marshall SE, Davies JD, Waldmann H. Mechanisms of peripheral tolerance and suppression induced by monoclonal antibodies to CD4 and CD8. Immunol Rev 1996; 149: 5.
30. Helderman JH. Review and preview of anti-T-cell antibodies. Transplant Proc 1995; 27: 8.
31. Murakami Y, Kong YY, Nishimura Y, et al. Prevention of anti-T cell receptor alpha beta monoclonal antibody-induced side-effects by treatment with cyclosporin A without interference of monoclonal antibody-induced immunosuppression in mice. Immunology 1995; 86: 238.
32. Hooks MA, Wade CS, Millikan WJ Jr. Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation. Pharmacotherapy 1991; 11: 26.
33. Jang Y, Lincoff AM, Plow EF, Topol EJ. Cell adhesion molecules in coronary artery disease. J Am Coll Cardiol 1994; 24: 1591.
34. Azuma H, Heemann UW, Tullius SG, Tilney NL. Cytokines and adhesion molecules in chronic rejection. Clin Transplant 1994; 8: 168.
35. Rodriguez-Iturbe B. Cellular adhesion molecules in transplantation. Transplant Proc 1996; 28: 3285.
36. Isobe M, Yagita H, Okumura K, Ihara A. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science 1992; 255: 1125.
37. Lin H, Wie RQ, Gordon D, Linsley P, Turka LA, Bolling SF. Review of CTLA4Ig use for allograft immunosuppression. Transplant Proc 1994; 26: 3200.
38. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, et al. Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. J Immunol 1997; 158: 29.
39. Omary MB, Trowbridge IS, Letarte M, Kagnoff MF, Isacke CM. Structural heterogeneity of human Pgp-1 and its relationship with p85. Immunogenetics 1988; 27: 460.
40. Picker LJ, Nakache M, Butcher EC. Monoclonal antibodies to human lymphocyte homing receptors define a novel class of adhesion molecules on diverse cell types. J Cell Biol 1989; 109: 927.
41. Jalkanen S, Bargatze RF, de los Toyos J, Butcher EC. A lymphoid cell surface protein involved in endothelial cell recognition and lymphocyte homing in man. Eur J Immunol 1986; 16: 1195
42. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 1992; 89: 12160.
43. Stamenkovic I, Aruffo A, Amiot M, Seed B. The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. EMBO J 1991; 10: 343.
44. Tölg C, Hofmann M, Herrlich P, Ponta H. Splicing choice from ten variant exons establishes CD44 variability. Nucleic Acids Res 1993; 21: 1225.
45. Jalkanen S, Jalkanen M, Bargatze R, Tammi M, Butcher EC. Biochemical properties of glycoproteins involved in lymphocyte recognition of high endothelial venules in man. J Immunol 1988; 141: 1615.
46. Weber B, Rösel M, Arch R, Möller P, Zöller M. Expression of variant isoforms of CD44 during ontogeny of the rat: evidence for divergent functions of distinct exon combinations. Differentiation 1996; 60: 17.
47. Arch R, Wirth K, Hofmann M, et al. Participation of a metastasis-inducing splice variant of CD44 in normal immune response. Science 1992; 257: 682.
48. Huet S, Groux H, Caillou B, Valentin H, Prieur AM, Bernard A. CD44 contributes to T cell activation. J Immunol 1989; 143: 798.
49. Shimizu Y, van Seventer GA, Siraganian R, Wahl L, Shaw S. Dual role of the CD44 molecule in T-cell adhesion and activation. J Immunol 1989; 143: 2457.
50. Denning SM, Le PT, Singer KH, Haynes BF. Antibodies against the CD44 p80, lymphocyte homing receptor molecule augment human peripheral blood T cell activation. J Immunol 1990; 144: 7.
51. Pierres A, Lipcey C, Mawas C, Olive D. A unique CD44 monoclonal antibody identifies a new T cell activation pathway. Eur J Immunol 1992; 22: 413.
52. Galandrini R, Albi N, Tripodi G, et al. Antibodies to CD44 trigger effector functions of human T cell clones. J Immunol 1993; 150: 4225.
53. Naujokas MF, Morin M, Anderson MS, Peterson M, Miller J. The chondroitin sulfate form of invariant chain can enhance stimulation of T cell responses through interaction with CD44. Cell 1993; 74: 257.
54. Moll J, Schmidt A, van der Putten H, et al. Accelerated T cell responsiveness in variant CD44 expressing transgenic mice. J Immunol 1996; 156: 2085.
55. Sommer F, Huber M, Röllinghoff M, Lohoff M. CD44 plays a co-stimulatory role in murine T cell activation: ligation of CD44 selectively co-stimulates IL-2 production, but not proliferation in TCR-stimulated murine Th1 cells. Int Immunol 1995; 7: 1779.
56. Taher TE, Smit L, Griffioen AW, Schilder-Tol EJ, Borst J, Pals ST. Signaling through CD44 is mediated by tyrosine kinases: association with p56lck in T lymphocytes. J Biol Chem 1996; 271: 2863.
57. Palmieri G, Gismondi A, Galandrini R, et al. Interaction of natural killer cells with extracellular matrix induces early intracellular signaling events and enhances cytotoxic functions. Nat Immun 1996; 15: 147.
58. Galluzzo E, Albi N, Fiorucci S, et al. Involvement of CD44 variant isoforms in hyaluronate adhesion by human activated T cells. Eur J Immunol 1995; 25: 2932.
59. Guo Y, Wu Y, Shinde S, Sy MS, Aruffo A, Lia Y. Identification of a costimulatory molecule rapidly induced by CD40L as CD44H. J Exp Med 1996; 184: 955.
60. Benz PS, Fan X, Wuthrich RP. Enhanced tubular epithelial CD44 expression in MRL-lpr lupus nephritis. Kidney Int 1996; 50: 156.
61. Hayashi Y, Haneji N, Hamano H, Yanagi K, Takahashi M, Ishimaru N. Effector mechanism of experimental autoimmune sialadenitis in the mouse model for primary Sjogren's syndrome. Cell Immunol 1996; 171: 217.
62. Verdrengh M, Holmdahl R, Tarkowski A. Administration of antibodies to hyaluronan receptor (CD44) delays the start and ameliorates the severity of collagen II arthritis. Scand J Immunol 1995; 42: 353.
63. Nishikawa K, Andres G, Bhan AK, et al. Hyaluronate is a component of crescents in rat autoimmune glomerulonephritis. Lab Invest 1993; 68: 146.
64. Zeine R, Owens T. Direct demonstration of the infiltration of murine central nervous system by Pgp-1/CD44 high CD45RB(low) CD4+ T cells that induce experimental allergic encephalomyelitis. J Neuroimmunol 1992; 40: 57.
65. Budd RC, Schumacher JH, Winslow G, Mosmann TR. Elevated production of interferon-gamma and interleukin 4 by mature T cells from autoimmune lpr mice correlates with Pgp-1 (CD44) expression. Eur J Immunol 1991; 21: 1081.
66. Rosenberg WM, Prince C, Kaklamanis L, et al. Increased expression of CD44v6 and CD44v3 in ulcerative colitis but not colonic Crohn's disease. Lancet 1995; 345: 1205.
67. VanTwuyver E, Kast WM, Mooijaart RJD, Melief CJM, DeWaal LP. Induction of transplantation tolerance by intravenous injection of allogeneic lymphocytes across an H-2 class II mismatch: different mechanisms operate in tolerization across an H-2 class I vs. H-2 class II disparity. Eur J Immunol 1990; 20: 441.
68. Claas FHJ, DeKoster HS, Lagaaij EL, VanRood JJ. A molecular mechanism of T cell downregulation by blood transfusion. Exp Nephrol 1993; 1: 134.
69. Heeg K, Wagner H. Induction of peripheral tolerance to class I major histocompatibility complex (MHC) alloantigens in adult mice: transfused class I MHC-incompatible splenocytes veto clonal responses of antigen-reactive Lyt-2+ T cells. J Exp Med 1990; 172: 719.
70. Middleton D, Martin J, Douglas J, McClelland M. Transfusion of one HLA-DR antigen-matched blood to potential recipients of a renal allograft. Transplantation 1994; 58: 845.
71. Bayle F, Masson D, Zaoui P, et al. Beneficial effect of one HLA haplo- or semi-identical transfusion versus three untyped blood units on alloimmunization and acute rejection episodes in first renal allograft recipients. Transplantation 1995; 59: 719.
72. Matzku S, Wenzel A, Liu S, Zöller M. Antigenic differences between metastatic and nonmetastatic BSp73 rat tumor variants characterized by monoclonal antibodies. Cancer Res 1989; 49: 1294.
73. Zöller M, Schuhmacher J, Reed J, Maier-Borst W, Matzku S. Establishment and characterization of monoclonal antibodies against an octahedral gallium chelate. J Nucl Med 1992; 33: 1366.
74. Cattoretti G, Berti E, Schiró R, D'Amato L, Valeggio C, Rilke F. Improved avidin-biotin-peroxidase complex (ABC) staining. Histochem J 1988; 20: 75.
75. Lefkovits I, Waldmann H. Limiting dilution analysis of cells in the immune system. Cambridge: University Press, 1978.
76. Engvall E, Perlman P. Enzyme-linked immunosorbent assay (ELISA): quantitative assay of immunoglobulin G. Immunochemistry 1971; 8: 871.
77. Ferguson CJ, vonRuhland C, Parry-Jones DJ, Griffiths DF, Salaman JR, Williams JD. Low dose cyclosporin nephrotoxicity in the rat. Nephrol Dial Transplant 1993; 8: 1259.
78. Briggs JD. A critical review of immunosuppressive therapy. Immunol Lett 1991; 29: 89.
79. Koopman G, Heider KH, Horst E, et al. Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44. J Exp Med 1993; 177: 897.
80. Emmrich F, Burmester G, Horneff G, et al. Treatment of autoimmune diseases and graft rejection with anti-CD4 antibodies. Z Gesamte Inn Med 1992; 47: 500.
81. Bushell A, Morris PJ, Wood KJ. Induction of operational tolerance by random blood transfusion combined with anti-CD4 antibody therapy: a protocol with significant clinical potential. Transplantation 1994; 58: 133.
82. Cooperative Clinical Trials in Transplantation Research Group. Murine OKT4A immunosuppression in cadaver donor renal allograft recipients: a Cooperative Clinical Trials in Transplantation pilot study. Transplantation 1997; 63: 1243.
83. Delmonico FL, Cosimi AB. Anti-CD4 monoclonal antibody therapy. Clin Transplant 1996; 10: 397.
84. DeGrendele HC, Estess O, Siegelman MH. Requirement for CD44 in activated T cell extravasation into an inflammatory site. Science 1997; 278: 672.
85. Hamano K, Ito H, Bushell A, Wood KJ, Esato K. The induction of operational tolerance is not prevented by simultaneous administration of cyclosporin Al. Transpl Int 1997; 10: 293.
86. Omoto K, Nishimura Y, Nomoto K, et al. Anti-CD4 monoclonal antibody reduces the dose of cyclophosphamide required to induce tolerance to H-2 haplotype identical skin allografts in mice. Immunobiology 1996; 195; 16.
87. Flanagan WM, Corthesy B, Bram RJ, Crabtree GR. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature 1989; 352: 803.
88. Saitovitch D, Bushell A, Mabbs DW, Morris PJ, Wood KJ. Kinetics of induction of transplantation tolerance with a nondepleting anti-CD4 monoclonal antibody and donor-specific transfusion before transplantation: a critical period of time is required for development of immunological unresponsiveness. Transplantation 1996; 61: 1642.
89. + T cell regulation during the induction phase of response. Eur J Immunol 1995; 25: 2643.
90. Motoyama K, Arima T, Lehmann M, Flye MW. Tolerance to heart and kidney grafts induced by nondepleting anti-CD4 monoclonal antibody (RIB 5/2) versus depleting anti-CD4 monoclonal antibody (Ox38) with donor antigen administration. Surgery 1997; 213: 219.
91. Yin D, Fathman CG. CD4-positive suppressor cells block allotransplant rejection. J Immunol 1995; 154: 6339.
92. Arima T, Lehmann M, Flye MW. Induction of donor specific transplantation tolerance to cardiac allografts following treatment with nondepleting (RIB 5/2) or depleting (Ox38) anti-CD4 mAb plus intrathymic or intravenous donor alloantigen. Transplantation 1997; 63: 284.
93. Marshall SE, Cobbold SP, Davies JD, Martin GM, Phillips JM, Waldmann H. Tolerance and suppression in a primed immune system. Transplantation. 1996; 62: 1614.
94. Hale DA, Gottschalk R, Maki T, Monaco AP. Use of CTLA4-Ig in combination with conventional immunosuppressive agents to prolong allograft survival. Transplantation 1997; 64: 897.
95. Boiling SF, Lin H, Wie RQ, Linsley P, Turka LA. The effect of combination cyclosporin and CTLA4-Ig therapy on cardiac allograft survival. J Surg Res 1994; 75: 60.
96. Jordan SC, Matsumara Y, Zuo XJ, Marchevsky A, Linsley P, Matloff J. Donor-specific transfusions enhance the immunosuppressive effects of single-dose cyclosporin A and CTLA4-Ig but do not result in long-term graft acceptance in a histoincompatible model of rat lung allograft rejection. Transpl Immunol 1996; 4: 33.
97. Yin D, Fathman CG. Induction of tolerance to heart allografts in high responder rats by combining anti-CD4 with CTLA4Ig. J Immunol 1995; 15: 1655.
98. Yin D, Sankary HN, Williams J, Krieger N, Fathman CG. Induction of tolerance to small bowel allografts in high responder rats by combining anti-CD4 with CTLA4Ig. Transplantation 1996; 62: 1537.